While the checkpoint blockers that include anti-CTLA-4 and anti-programmed cell death protein-1/ligand-1 (PD1/PDL1) have demonstrated unprecedented efficacy in treating a number of cancers such as non-small cell lung cancer, melanoma, and urothelial carcinoma, the response rate remains unsatisfactory [2]. Here, CTLA4 is linked to melanoma.